Publications de Ece Kadioglu | EPFL Graph Search

Determinants of tumor resistance to anti-angiogenic immunotherapy in mouse models of Kras-mutant NSCLC

Ioanna Keklikoglou, Sina Nassiri, Etienne Meylan, Michele De Palma, Ece Kadioglu, Chiara Cianciaruso, Bruno Torchia, Alan Nicolas Thierry Guichard, Amaia Martinez Usatorre

AMER ASSOC CANCER RESEARCH2021

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Ioanna Keklikoglou, Nadine Fournier, Sina Nassiri, Etienne Meylan, Michele De Palma, Ece Kadioglu, Chiara Cianciaruso, Bruno Torchia, Gael Luis Boivin, Alan Nicolas Thierry Guichard, Amaia Martinez Usatorre

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of nonsmall cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic d ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Anti-angiogenic immunotherapy for lung cancer

Ece Kadioglu

Lung cancer is the leading cause of cancer-associated deaths worldwide. Platinum-based chemotherapy is the most common therapeutic approach in advanced non-small cell lung cancer (NSCLC), particularly for tumors that carry non-druggable activating mutation ...

EPFL2019

Periostin Limits Tumor Response to VEGFA Inhibition

Ioanna Keklikoglou, Michele De Palma, Ece Kadioglu, Axel Bellotti

Resistance to antiangiogenic drugs limits their applicability in cancer therapy. Here, we show that revascularization and progression of pancreatic neuroendocrine tumors (PNETs) under extended vascular-endothelial growth factor A (VEGFA) blockade are depen ...

2018

The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and neuroendocrine pancreatic tumors

Michele De Palma, Ece Kadioglu

Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation and metastasis, which can offset the effects of chemotherapy, radiation, and anti-angiogenic therapy. Here, we show that the kinase switch contro ...

Amer Assoc Cancer Research2017

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Michele De Palma, Ece Kadioglu, Nicolo Rigamonti, Antonino Cassarà, Céline Wyser Rmili, Damya Laoui

Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) are proangiogenic cytokines that sustain tumor angiogenesis and limit antitumor immunit ...

American Association for the Advancement of Science2017

Cancer metastasis: Perivascular macrophages under watch

Michele De Palma, Ece Kadioglu

TIE2-expressing macrophages cluster around blood vessels and sustain tumor angiogenesis. Harney and colleagues now use live imaging of mouse mammary tumors to show that these perivascular macrophages also promote the transient opening of tumor blood vessel ...

American Association for Cancer Research2015

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade

Ioanna Keklikoglou, Michele De Palma, Ece Kadioglu, Nicolo Rigamonti, Céline Wyser Rmili

Angiopoietin-2 (ANG2/ANGPT2) is a context-dependent TIE2 receptor agonist/antagonist and proangiogenic factor. Although ANG2 neutralization improves tumor angiogenesis and growth inhibition by vascular endothelial growth factor (VEGF)-A signaling blockade, ...

Elsevier2014